Guide

KPV peptide: what the research found, and what it did not

KPV is three amino acids clipped off the end of a hormone your body already makes. It has a real research literature behind it, and every study in that literature used mice, cultured cells, rabbits or a piece of donated skin. No clinical trial in people has tested it.

Published September 19, 2026

This page reports what published studies found. It is not medical advice, no provider-patient relationship is created by reading it, and nothing here is a recommendation to use any compound. Talk with a licensed clinician about your own situation. Read the full disclaimer.

Three amino acids off the end of a hormone

KPV is lysine, proline and valine, in that order. Those three are the tail end of alpha-melanocyte-stimulating hormone, a signalling molecule the body makes itself, and in the literature KPV is usually written as alpha-MSH(11-13). Alpha-MSH has long been described as anti-inflammatory, and the reason KPV became interesting is the finding that this short tail seems to carry a good deal of that behaviour without needing the rest of the hormone.

Three amino acids is very small for a peptide. BPC-157 is fifteen and insulin is fifty-one. That size is part of why it shows up in delivery research: small peptides are easier to move across barriers like skin and gut wall than large ones.

No trial has tested it in people

That is the single most important fact about KPV and it sits oddly against how confidently it is sold. Roughly thirty-eight thousand people look this compound up every month, and what they find is mostly product pages. The underlying science is real and none of it has reached a person in a trial.

What has actually been studied

Gut inflammation, in mice

The strongest thread. A 2008 study in Gastroenterology examined KPV in two mouse models of colitis, along with human intestinal epithelial and immune cells, and identified uptake through PepT1, a transporter that carries di- and tripeptides and which is induced in the colon during inflammatory bowel disease, as a route by which it acts. A separate 2008 paper in Inflammatory Bowel Diseases tested the same tripeptide in two further murine models of inflammatory bowel disease.

Note what that mechanism implies. PepT1 sits in the intestine. The route being studied was the gut, not a syringe.

General inflammation, in mice

A 2003 paper in the Journal of Pharmacology and Experimental Therapeutics compared KPV against alpha-MSH and other melanocortin fragments in a mouse model of crystal-induced peritonitis, given systemically, as a way of working out which part of the parent hormone carries the anti-inflammatory effect.

Corneal healing, in rabbits

A 2006 study in Experimental Eye Research abraded the corneal epithelium of rabbits in both eyes and applied KPV topically, photographing and measuring the remaining epithelial defect every twelve hours, while examining the role of nitric oxide in the effect. Topical, to the eye, in rabbits.

Skin and liver cells, in dishes

Two recent papers work in cell lines. A 2025 study in Tissue and Cell exposed human HaCaT keratinocytes, an immortalised skin cell line, to fine particulate matter and reported that KPV reduced the resulting oxidative stress and inflammatory signalling. A 2026 study in Cytotechnology used HepG2 liver cells loaded with oleic acid as a model of early fatty liver and reported reduced lipid accumulation through a ROS-dependent pathway. Both are cells in plates, not organisms.

Getting it through skin

A 2017 paper in the Journal of Pharmaceutical Sciences tested iontophoresis, microneedles and the two combined to move KPV across dermatomed human skin, taking advantage of the peptide carrying a positive charge below pH 7. This is engineering work about delivery rather than a study of any effect in a person.

What “benefits” can honestly mean here

Findings in mice, rabbits and cell lines are genuine findings. They are also the earliest stage of a process that usually ends in disappointment: most compounds that work in a mouse model do not go on to work in people, which is why trials exist at all.

So the accurate way to describe KPV today is that it has produced anti-inflammatory effects in several preclinical models, and that nobody knows whether it does anything for a person, because that study has not been run. Any page listing KPV's benefits as though they were established in humans has skipped that step.

On dosing

This site reports doses only when a study administered them to a stated population, and attributes each one to the study that used it. For KPV there is no such figure in people, so there is nothing for us to report. The amounts that circulate on seller sites and forums are conventions; they are not traceable to a trial, because there is no trial.

The route mismatch

Worth holding on to when reading marketing copy. KPV is sold mostly as a vial for injection. The research that gets cited for it is gut uptake through an intestinal transporter, topical application to a rabbit eye, cells in a dish, and pushing the molecule through skin with a current. Very little of it involves injecting the peptide, so evidence from those studies does not transfer cleanly to the product being sold.

Where it stands legally

KPV is not an FDA-approved drug. Vials sold online carry research-use labelling and are not intended for human use. Whether a compounding pharmacy may lawfully prepare a substance depends on FDA's bulk drug substance lists, and the legality guide sets out the three categories and what the 2026 committee vote did and did not decide.

KPV also turns up as one ingredient inside the KLOW blend, alongside GHK-Cu, BPC-157 and TB-500. What those mixtures contain, and why no study has tested them as mixtures, is covered in the blends guide.

What to ask before buying

• Which study is this claim from, and was it in people, an animal, or cells in a dish?
• By what route was it given in that study, and is that the route being sold here?
• Is there a lot-specific certificate of analysis whose lot number matches this vial?
• Is this research-use material, or something a licensed prescriber is prescribing?
• If a dosing chart is offered, what study is it derived from?

Common questions